BRPI1009257A2 - antagonista receptor de mineralocorticoide e métodos de uso. - Google Patents
antagonista receptor de mineralocorticoide e métodos de uso.Info
- Publication number
- BRPI1009257A2 BRPI1009257A2 BRPI1009257A BRPI1009257A BRPI1009257A2 BR PI1009257 A2 BRPI1009257 A2 BR PI1009257A2 BR PI1009257 A BRPI1009257 A BR PI1009257A BR PI1009257 A BRPI1009257 A BR PI1009257A BR PI1009257 A2 BRPI1009257 A2 BR PI1009257A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- receptor antagonist
- mineralocorticoid receptor
- mineralocorticoid
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15957809P | 2009-03-12 | 2009-03-12 | |
| PCT/US2010/026138 WO2010104721A1 (en) | 2009-03-12 | 2010-03-04 | Mineralocorticoid receptor antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009257A2 true BRPI1009257A2 (pt) | 2016-03-08 |
Family
ID=42139981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009257A BRPI1009257A2 (pt) | 2009-03-12 | 2010-03-04 | antagonista receptor de mineralocorticoide e métodos de uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8658638B2 (pt) |
| EP (1) | EP2406252B1 (pt) |
| JP (1) | JP5570536B2 (pt) |
| KR (1) | KR101312179B1 (pt) |
| CN (1) | CN102333773B (pt) |
| AU (1) | AU2010222902B2 (pt) |
| BR (1) | BRPI1009257A2 (pt) |
| CA (1) | CA2751901C (pt) |
| EA (1) | EA019179B1 (pt) |
| ES (1) | ES2542001T3 (pt) |
| MX (1) | MX2011009506A (pt) |
| WO (1) | WO2010104721A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| DK3160948T3 (en) | 2014-06-30 | 2019-02-18 | Astrazeneca Ab | BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS |
| JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| EP1697350B1 (en) * | 2003-12-19 | 2008-06-25 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| TWI431010B (zh) * | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
-
2010
- 2010-03-04 WO PCT/US2010/026138 patent/WO2010104721A1/en active Application Filing
- 2010-03-04 US US13/203,518 patent/US8658638B2/en not_active Expired - Fee Related
- 2010-03-04 CA CA2751901A patent/CA2751901C/en not_active Expired - Fee Related
- 2010-03-04 MX MX2011009506A patent/MX2011009506A/es active IP Right Grant
- 2010-03-04 ES ES10707770.3T patent/ES2542001T3/es active Active
- 2010-03-04 EA EA201171125A patent/EA019179B1/ru not_active IP Right Cessation
- 2010-03-04 KR KR1020117021231A patent/KR101312179B1/ko not_active IP Right Cessation
- 2010-03-04 AU AU2010222902A patent/AU2010222902B2/en not_active Ceased
- 2010-03-04 CN CN201080009314.8A patent/CN102333773B/zh not_active Expired - Fee Related
- 2010-03-04 BR BRPI1009257A patent/BRPI1009257A2/pt not_active IP Right Cessation
- 2010-03-04 EP EP20100707770 patent/EP2406252B1/en not_active Not-in-force
- 2010-03-04 JP JP2011554083A patent/JP5570536B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010222902A1 (en) | 2011-08-11 |
| ES2542001T3 (es) | 2015-07-29 |
| JP5570536B2 (ja) | 2014-08-13 |
| EA201171125A1 (ru) | 2012-02-28 |
| CN102333773A (zh) | 2012-01-25 |
| CN102333773B (zh) | 2014-04-16 |
| EP2406252B1 (en) | 2015-05-20 |
| CA2751901C (en) | 2013-08-06 |
| EA019179B1 (ru) | 2014-01-30 |
| EP2406252A1 (en) | 2012-01-18 |
| CA2751901A1 (en) | 2010-09-16 |
| US20110312954A1 (en) | 2011-12-22 |
| US8658638B2 (en) | 2014-02-25 |
| JP2012520302A (ja) | 2012-09-06 |
| AU2010222902B2 (en) | 2013-04-18 |
| WO2010104721A1 (en) | 2010-09-16 |
| KR101312179B1 (ko) | 2013-09-26 |
| MX2011009506A (es) | 2011-09-28 |
| KR20110124305A (ko) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911563A2 (pt) | uso de antagonista da progesterona | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| BRPI1008060A2 (pt) | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. | |
| BRPI0914004A2 (pt) | agentes de aglutinação de receptor notch1 e métodos de uso mesmo | |
| BRPI0906435A2 (pt) | anticorpos anti-cd79b e imunoconjugados e métodos de uso | |
| BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
| ECSP12012034A (es) | Antagonistas de pcsk9 | |
| BR112012015873A2 (pt) | antagonistas de receptores ccr2 e usos dos mesmos | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| BRPI1011321A2 (pt) | dispositivo de monitoramento de analito de métodos de uso | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| DOP2011000059A (es) | Composiciones de antagonistas de pd-1 y metodos de uso | |
| BRPI0915717A2 (pt) | ferramenta de avaliação de cascalho e métodos de uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| SMT201700064B (it) | Antagonisti di d2, metodi di sintesi e metodi di uso | |
| BRPI0915086A2 (pt) | detecção do uso de canabis | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112012005736A2 (pt) | di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas | |
| BRPI0919539A2 (pt) | antagonistas de receptor de opioide periférico e empregos dos mesmos | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |